Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct 2;12(10):e0184441.
doi: 10.1371/journal.pone.0184441. eCollection 2017.

Loss of long-term non-progressor and HIV controller status over time in the French Hospital Database on HIV - ANRS CO4

Affiliations

Loss of long-term non-progressor and HIV controller status over time in the French Hospital Database on HIV - ANRS CO4

Sophie Grabar et al. PLoS One. .

Abstract

Objectives: We studied the frequency and risk factors for loss of long-term non-progressor (LTNP) and HIV controller (HIC) status among patients identified as such in 2005 in the French Hospital Database on HIV (FHDH-ANRS CO4).

Methods: We selected patients who were treatment-naïve and asymptomatic in 2005 (baseline). Those with ≥8 years of known HIV infection and a CD4 cell nadir ≥500/mm3 were classified as LTNP and those with ≥10 years of known HIV infection and 90% of plasma viral load (VL) values ≤500 copies/ml in the absence of cART as HIC. cART initiation without loss of status and death from non AIDS-defining causes were considered as competing events.

Results: After 5 years of follow-up, 33% (95%CI; 27-42) of 171 LTNP patients and 17% (95%CI; 10-30) of 72 HIC patients had lost their status. In multivariable analyses, loss of LTNP status was associated with lower baseline CD4 cell counts and CD4/CD8 ratios. Only VL was significantly associated with loss of HIC status after adjustment for the baseline CD4 cell count, the CD4/CD8 ratio, and concomitant LTNP status. The hazard ratio for loss of HIC status was 5.5 (95%CI, 1.5-20.1) for baseline VL 50-500 vs ≤50 cp/mL, after adjustment for the baseline CD4 cell count.

Conclusions: One-third of LTNP and one-fifth of HIC patients lost their status after 5 years of follow-up, raising questions as to the possible benefits and timing of ART initiation in these populations.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: Dominique Costagliola was a member of the French Gilead HIV board up to 2015. In the past 3 years, she gave lectures for Janssen-Cilag, Merck-Sharp & Dohme-Chibret, ViiV and received travel/accommodations/meeting expenses from Gilead, ViiV, Janssen-Cilag. She conducted post-marketing studies for Janssen-Cilag, Merck-Sharp & Dohme-Chibret and ViiV. She is currently a consultant for Innavirvax. Laurence Weiss was a member of the Advisory board for Bristol Myers Squibb (up to 2015), of the Regional Advisory board Gilead (2016). In the past 3 years, he gave lectures for Janssen-Cilag, Merck-Sharp & Dohme-Chibret and received travel/accommodations/meeting expenses from Gilead, Bristol Myers Squibb, and Janssen-Cilag. He is currently a consultant for Bristol Myers Squibb (immune-oncology). Sophie Abgrall is a member of the French Janssen-Cilag board. In the past 3 years, she gave lectures for Gilead and ViiV, and received travel/accommodations expenses from Gilead, ViiV and Janssen-Cilag. Sophie Grabar gave a lecture for Gilead. Gilles Pialoux have received research grants from Gilead and BMS. He participated on advisory boards or received travel/accommodations expenses from Gilead, MSD, Janssen, BMS, Abbvie and ViiVhealthcare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1
Cumulative incidence of loss of LTNP (panel A) and HIV controller (panel B) status, treatment initiation and non AIDS deaths since 2005. A: Long-term non-progressors (n = 171). B: HIV controllers (n = 72).

Similar articles

Cited by

References

    1. Gurdasani D, Iles L, Dillon DG, Young EH, Olson AD, Naranbhai V, et al. A systematic review of definitions of extreme phenotypes of HIV control and progression. AIDS 2014; 28(2):149–162. doi: 10.1097/QAD.0000000000000049 - DOI - PMC - PubMed
    1. Madec Y, Boufassa F, Porter K, Prins M, Sabin C, d'Arminio Monforte A, et al. Natural history of HIV-control since seroconversion. AIDS 2013; 27(15):2451–2460. doi: 10.1097/01.aids.0000431945.72365.01 - DOI - PubMed
    1. Noel N, Lerolle N, Lecuroux C, Goujard C, Venet A, Saez-Cirion A, et al. Immunologic and Virologic Progression in HIV Controllers: The Role of Viral "Blips" and Immune Activation in the ANRS CO21 CODEX Study. PLoS One 2015; 10(7):e0131922 doi: 10.1371/journal.pone.0131922 - DOI - PMC - PubMed
    1. Leon A, Perez I, Ruiz-Mateos E, Benito JM, Leal M, Lopez-Galindez C, et al. Rate and predictors of progression in elite and viremic HIV-1 controllers. AIDS 2016; 30(8):1209–1220. doi: 10.1097/QAD.0000000000001050 - DOI - PubMed
    1. Mandalia S, Westrop SJ, Beck EJ, Nelson M, Gazzard BG, Imami N. Are long-term non-progressors very slow progressors? Insights from the Chelsea and Westminster HIV cohort, 1988–2010. PLoS One 2012; 7(2):e29844. - PMC - PubMed

Substances